News
Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?
Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The company's share price was up 15.8% as of 1:45 p.m. ET. At the same point in time
Why Tempus AI Stock Is Skyrocketing Today
Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear
What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?
The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.
Three
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes
Is AbbVie Stock a Buy?
It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now
The S&P 500 has dropped 10% or more nine times since 2010, not including the current sell-off. However, the index has delivered an average return of 18% in the year following the start date of these
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next
Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff plans, then bounced back big once he said he would pause expanded
Where Will Eli Lilly Be in 5 Years?
What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer, and
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since
Why Pfizer Stock Topped the Market on Tuesday
On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE). Somewhat counterintuitively, this week's rise came after the company announced it was ending the
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?
Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1
EQS-Adhoc: Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Viking Therapeutics (NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer's
1 Deeply Undervalued Stock to Buy in the Market Correction
Pfizer's (NYSE: PFE) shares have been southbound for the better part of three years, partly because it was unable to repeat its incredible financial performance during the early pandemic years
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with
This S&P 500 Stock Soared While the Market Plunged. Is It Still a Buy Now?
Roughly four out of five S&P 500 (SNPINDEX: ^GSPC) stocks are in negative territory in 2025. Most of those stocks weren't immune to the meltdown that occurred in recent days following President
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark, and it's looking like things might be about to get even worse for this particular pocket of
Humana’s Initiatives Deliver Improved Health Outcomes in Communities
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, today released its 2024 Impact Report, showcasing the company’s dedication to improving health outcomes and
2 Top Dividend Stocks That Could Set You Up for Life
With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.
For one, dividend-paying companies tend to
3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now
If you're a dividend investor, now can be an ideal time to go bargain-hunting. The stock market is in the midst of a broad sell-off, with investors dumping all types of stocks, both bad ones and
3 No-Brainer Growth Stocks to Buy for Less Than $100
Don't let the sell-off in the markets scare you off: Now may be an ideal time to buy stocks. Even if you don't have a lot of money that you can afford to invest, there are many great stocks you can




